Effectiveness of a personal health coaching intervention (diabetescoach) in patients with type 2 diabetes: protocol for an open-label, pragmatic randomised controlled trial

被引:3
|
作者
Hohberg, Vivien [1 ]
Kreppke, Jan-Niklas [1 ]
Kohl, Jan [2 ]
Seelig, Eleonora [3 ,4 ]
Zahner, Lukas [1 ]
Streckmann, Fiona [1 ,5 ]
Gerber, Markus [1 ]
Konig, Daniel [2 ,6 ]
Faude, Oliver [1 ]
机构
[1] Univ Basel, Dept Sport Exercise & Hlth, Basel, Switzerland
[2] Univ Freiburg, Inst Sports & Sport Sci, Freiburg, Germany
[3] Univ Hosp Basel, Endocrinol Diabetol & Metab, Basel, Switzerland
[4] Cantonal Hosp Basel Landschaft, Endocrinol & Diabetol, Vestal, Switzerland
[5] Univ Hosp Basel, Onkol, Basel, Switzerland
[6] Univ Vienna, Inst Nutr Exercise & Hlth, Vienna, Austria
来源
BMJ OPEN | 2022年 / 12卷 / 06期
关键词
LIPOPROTEIN INSULIN-RESISTANCE; LIFE-STYLE INTERVENTION; PHYSICAL-ACTIVITY; POSITION STATEMENT; METABOLIC SYNDROME; SELF-EFFICACY; OBESE ADULTS; EXERCISE; BEHAVIOR; RISK;
D O I
10.1136/bmjopen-2021-057948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The widespread prevalence of type 2 diabetes (T2D) not only influences patients' daily lives but also has an economic impact on society. Increasing physical activity and a healthy diet can delay the progression of T2D. Although there are evidence-based recommendations on diet and physical activity, patients with T2D have difficulties implementing them. An appropriate lifestyle intervention can address this problem. Methods and analysis This study is based on the need to develop an intervention that helps patients to establish behavioural changes in order to achieve glycaemic control. The intervention will be evaluated in a monocentric, open-label, pragmatic, two-arm randomised controlled trial with a sample ratio of 1:1 and a parallel design. This superiority study will be conducted in Switzerland. All enrolled patients (n=90) will receive the standard medical treatment for T2D. The intervention group will receive personal health coaching by telephone and access to a smartphone and web application for 1 year. The control group will receive access to the application for 1 year and a one-time written diet and exercise recommendation. The primary outcomes are objectively measured physical activity and glycated haemoglobin. Secondary outcomes are self-reported physical activity, nutrition, cognitive mediators of changes in sport-related behaviour, blood values, medication and nutritional supplements, anthropometric data, quality of life, neuropathy and cost-effectiveness. All outcomes will be measured at baseline, at 27 weeks after inclusion and at 54 weeks after inclusion. The recruitment of participants and the measurements will be completed after 2 years. Linear mixed-effects models will be applied for each outcome variable to analyse the intervention effects. Ethics and dissemination This study was approved by the Ethics Committee North-western and Central Switzerland in February 2021 (ref: 2020-02755). All participants will be required to provide written informed consent. The results will be published in international peer-reviewed journals.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [11] Effectiveness of patients' involvement in a medical and nursing pain education programme: a protocol for an open-label randomised controlled trial including qualitative data
    Serafini, Alice
    Rossi, Maria Grazia
    Alberti, Sara
    Borellini, Erika
    Contini, Annamaria
    Cernesi, Simone
    D'Amico, Roberto
    Crescitelli, Matias Eduardo Diaz
    Ferri, Paola
    Fornaciari, Davide
    Ghirotto, Luca
    Giugni, Linda
    Lui, Fausta
    Rossi, Francesca
    Costantini, Riccardo Cuoghi
    Santori, Valentino
    Padula, Maria Stella
    BMJ OPEN, 2024, 14 (01):
  • [12] Multifactorial Intervention on Type 2 Diabetes (MIDiab) Study: A multicenter,open-label, randomized, parallel controlled, community trial
    Wang, Yupeng
    Guan, Qingbo
    Hou, Xu
    Zhang, Xu
    Zhang, Haiqing
    Xu, Chao
    Jing, Fei
    Ma, Shizhan
    Shao, Shanshan
    Zhao, Meng
    Guo, Qingling
    Zhong, Fang
    Gao, Ling
    Zhao, Jiajun
    JOURNAL OF DIABETES, 2020, 12 (11) : 862 - 864
  • [13] Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
    Ruscitti, Piero
    Masedu, Francesco
    Alvaro, Saverio
    Airo, Paolo
    Battafarano, Norma
    Cantarini, Luca
    Cantatore, Francesco Paolo
    Canino, Giorgio
    D'Abrosca, Virginia
    Frassi, Micol
    Frediani, Bruno
    Iacone, Daniela
    Liakouli, Vasiliki
    Maggio, Roberta
    Mule, Rita
    Pentane, Ilenia
    Prevete, Immacolata
    Sinigaglia, Luigi
    Valenti, Marco
    Viapiana, Ombretta
    Cipriani, Paola
    Giacomelli, Roberto
    PLOS MEDICINE, 2019, 16 (09)
  • [14] Effectiveness of general practice based, practice nurse led telephone coaching on glycaemic control of type 2 diabetes: the Patient Engagement And Coaching for Health (PEACH) pragmatic cluster randomised controlled trial
    Blackberry, Irene D.
    Furler, John S.
    Best, James D.
    Chondros, Patty
    Vale, Margarite
    Walker, Christine
    Dunning, Trisha
    Segal, Leonie
    Dunbar, James
    Audehm, Ralph
    Liew, Danny
    Young, Doris
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [15] Efficacy and tolerability of novel triple combination therapy in drug-naive patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial
    Kim, Nam Hoon
    Lim, Soo
    Kwak, Soo Heon
    Moon, Min Kyong
    Moon, Jun Sung
    Lee, Yong-ho
    Cho, Ho Chan
    Lee, Juneyoung
    Kim, Sin Gon
    BMJ OPEN, 2018, 8 (09):
  • [16] Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial
    de Bruin, Marijn
    Oberje, Edwin J. M.
    Viechtbauer, Wolfgang
    Nobel, Hans-Erik
    Hiligsmann, Mickael
    van Nieuwkoop, Cees
    Veenstra, Jan
    Pijnappel, Frank J.
    Kroon, Frank P.
    van Zonneveld, Laura
    Groeneveld, Paul H. P.
    van Broekhuizen, Marjolein
    Evers, Silvia M. A. A.
    Prins, Jan M.
    LANCET INFECTIOUS DISEASES, 2017, 17 (06): : 595 - 604
  • [17] 'Vidangadi Lauha' for obese type 2 diabetes mellitus patients - An open-label randomized controlled clinical trial
    Khobarkar, Punam
    Gulhane, Jayant
    Nakanekar, Amit
    JOURNAL OF AYURVEDA AND INTEGRATIVE MEDICINE, 2024, 15 (01)
  • [18] Qatar Diabetes Mobile Application Trial (QDMAT): an open-label randomised controlled trial to examine the impact of using a mobile application to improve diabetes care in type 2 diabetes mellitus—a study protocol
    Noor Suleiman
    Meis Alkasem
    Zaina Al Amer
    Obada Salameh
    Noora Al-Thani
    Mohammad Khair Hamad
    Khaled Baagar
    Ibrahem Abdalhakam
    Manal Othman
    Ragae Dughmosh
    Dabia Al-Mohanadi
    Ali Al Sanousi
    Mohammed Bashir
    Odette Chagoury
    Shahrad Taheri
    Abdul-Badi Abou-Samra
    Trials, 23
  • [19] Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial
    Marsden, John
    Stillwell, Garry
    James, Kirsty
    Shearer, James
    Byford, Sarah
    Hellier, Jennifer
    Kelleher, Michael
    Kelly, Joanna
    Murphy, Caroline
    Mitcheson, Luke
    LANCET PSYCHIATRY, 2019, 6 (05): : 391 - 402
  • [20] Effectiveness and cost-effectiveness of duloxetine added to usual care for patients with chronic pain due to hip or knee osteoarthritis: protocol of a pragmatic open-label cluster randomised trial (the DUO trial)
    van den Driest, Jacoline J.
    Schiphof, Dieuwke
    Luijsterburg, Pim A. J.
    Koffeman, Aafke R.
    Koopmanschap, Marc A.
    Bindels, Patrick J. E.
    Bierma-Zeinstra, Sita M. A.
    BMJ OPEN, 2017, 7 (09):